High-dose Olanzapine Versus Clozapine in Treatment-resistant Schizophrenia: A Systematic Review and Meta-analysis of Randomized Controlled Trials
While this meta-analysis revealed no significant difference in efficacy between clozapine and HDO for most outcomes, HDO did show a significant efficacy advantage over clozapine in the treatment of negative symptoms in adults with TRS. Adverse events were more frequently reported in the clozapine group, suggesting a more favorable safety profile for HDO. These results support HDO as a viable and potentially safer alternative to clozapine in the management of TRS.
Authors
- João Pedro Gonçalves Pacheco (ORCID: https://orcid.org/0000-0002-2871-7420)
- LUÍSA MENDES ARAÚJO
- Laura Mora (ORCID: https://orcid.org/0000-0002-2505-2486)
- Martin Kotochinsky
- Pandora Eloa Oliveira Fonseca
- Diogo Carrazzoni Godoi
Institutions
- Universidad Nacional de Cuyo (AR)
- Universidade Federal de Santa Maria (BR)
- Universidade Federal de Campina Grande (BR)
- Universidad Metropolitana (CO)
- Instituto Federal de Educação, Ciência e Tecnologia do Pará (BR)
- Hospital Alemán (AR)
- Universidade Federal do Pará (BR)
- Cardiff University (GB)
Publication Details
- Journal
- Journal of Psychiatric Practice
- Published
- 2026-03-01
- DOI
- https://doi.org/10.1097/pra.0000000000000916
- Primary Topic
- Schizophrenia research and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00